Furthermore, we explored the role of NLRP3 inflammasome activation in AML chemotherapy, and found that the killing effect of ADR or DNR on leukemia cells was reversed by LPS-induced NLRP3 activation (Figures 1H, I, Supplementary Figure 1D). This evidence concerns the gene NLRP3 and acute myeloid leukemia.